Patient Advocacy Groups Rate Pharmaceutical Industry Less Favorably for Second Year Due to Drug Cost Concerns.

Patient advocacy groups viewed the pharmaceutical industry less favorably for the second year in a row. Lingering worries about drug costs largely fueled this decline in reputation. These findings indicate a continuing trend. The primary factor contributing to the diminished reputation appears to be the persistent concerns surrounding pharmaceutical pricing practices, according to patient advocacy groups.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Alzheimer’s Research: 16 New Susceptibility Genes Identified Study Reveals Startling Impact of Abrupt PEPFAR Funding Cuts Study Maps Brain’s Real-Time Speech Processing Using AI and Electrocorticography

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後